Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Molecular Profiling of Advanced Biliary Tract Cancers (COMPASS-B-MUHC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04318834
Recruitment Status : Recruiting
First Posted : March 24, 2020
Last Update Posted : March 24, 2020
Sponsor:
Collaborator:
Cancer Research Society
Information provided by (Responsible Party):
George Zogopoulos, McGill University Health Centre/Research Institute of the McGill University Health Centre

Brief Summary:
Biliary tract cancer (BTC) accounts for <1% of all cancers, but remains a highly fatal malignancy. Surgical resection is the only hope for cure, but most patients present with advanced disease when curative-intent surgery is not possible. The therapeutic options for patients with advanced disease are limited, primarily to chemotherapeutic regimens, which are based on empiric evidence without the use of biomarkers. These current treatment strategies have been largely ineffective in controlling the disease, resulting in poor survival outcomes of less than 1 year. An understanding of the molecular characteristics of biliary tract cancer may enable stratification of patients into therapies that target specific molecular alterations with greater efficacies and improved clinical outcomes. This study aims to investigate the feasibility and clinical utility of prospective molecular profiling of advanced biliary tract cancer. The primary endpoint of this study is to demonstrate the feasibility of returning whole genome sequencing results within 8 weeks of tumour biopsy for second-line treatment consideration (n=30 patients). In parallel, tumour whole transcriptome sequencing will be performed to identify actionable molecular alterations (e.g., fusion transcripts). Once the primary endpoint is met, the study will be expanded. Current funding allows expansion to 40 patients in total.

Condition or disease Intervention/treatment Phase
Biliary Tract Cancer Other: Tumour and germline molecular profiling Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Comprehensive Molecular Profiling of Advanced Biliary Tract Cancers for Better Treatment Selection: a McGill University Health Centre Study (COMPASS-B-MUHC)
Estimated Study Start Date : April 1, 2020
Estimated Primary Completion Date : April 2022
Estimated Study Completion Date : April 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Individuals with advanced biliary tract cancer
Following a tumour biopsy for molecular profiling, chemo-naive patients with advanced biliary tract cancer will receive first-line gemcitabine-based chemotherapy or an investigational drug on a participating clinical trial.
Other: Tumour and germline molecular profiling
Tumour whole genome sequencing, germline whole genome sequencing, tumour whole transcriptome sequencing




Primary Outcome Measures :
  1. Number of participants with tumour whole genome sequencing returned within 8 weeks [ Time Frame: 2 years ]
    We have estimated that 30 patients will be required to reach the primary end point, which will be met if we demonstrate that tumor whole genome sequencing data is available at 8 weeks from the tumour biopsy for 80% of patients.


Secondary Outcome Measures :
  1. Disease control rate [ Time Frame: 4 years ]
    Number of patients that achieve stability of disease (cancer) by imaging (RECIST criteria) with first-line standard chemotherapy, consisting of gemcitabine backbone.

  2. Progression-free survival rate [ Time Frame: 4 years ]
    Progression free survival (PFS) defined as the interval between the date of registration and the earliest date of disease progression or death due to any cause of patients treated with 1st line chemotherapy.

  3. Overall survival rate [ Time Frame: 4 years ]
    Overall survival (OS) defined as the interval between the date of registration and the date of death of patients treated with 1st line chemotherapy.

  4. Number of patients in whom at least 1 actionable mutation is identified [ Time Frame: 4 years ]
    based on whole genome sequencing or RNA sequencing analyses.

  5. Number of patients who received a targeted therapy (after first-line treatment) [ Time Frame: 4 years ]
    based on the identification of an actionable mutation by whole genome sequencing or RNA sequencing.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients must have a histological or radiological diagnosis of inoperable or metastatic BTC.
  • Patient must have a tumour that is amenable to a core needle biopsy.
  • Patients must have a measurable lesion by RECIST 1.1 in addition to the lesion that is going to be biopsied.
  • Patients must be fit to safely undergo a tumour biopsy as judged by the investigator.
  • Eastern Cooperative Group (ECOG) performance status ≤ 1.
  • Life expectancy of greater than 90 days.
  • Within 14 days of the proposed biopsy date, patients must have normal organ and marrow function.
  • Patients must undergo systemic treatment with gemcitabine-based regimens as first-line standard systemic palliative treatment with or without other investigational agents within a clinical trial.
  • Ability to understand and willing to sign a written informed consent document.

Exclusion Criteria:

  • Patients with one or more contraindications to tumour biopsy.
  • Patients who have had any prior chemotherapy or other anti-cancer agent in the advanced stage setting.
  • Patients who are currently on anti-cancer treatment.
  • Patients with known brain metastases.
  • Uncontrolled concurrent illness that would limit compliance with study requirements.
  • Any other condition that would contraindicate the patient's participation due to safety concerns or compliance with clinical study procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04318834


Contacts
Layout table for location contacts
Contact: George Zogopoulos, MD, PhD 514-934-1934 ext 76333 george.zogopoulos@mcgill.ca

Locations
Layout table for location information
Canada, Quebec
McGill University Health Centre Recruiting
Montréal, Quebec, Canada, H4A 3J1
Contact: Crystal Haigh, BA    514-934-1934 ext 76333    crystal.haigh@mail.mcgill.ca   
Contact: Adeline Cuggia, MSc    514-934-1934 ext 76333    cancer.pancreas@mcgill.ca   
Principal Investigator: George Zogopoulos, MD, PhD         
Sub-Investigator: Yifan Wang, MD         
Sponsors and Collaborators
McGill University Health Centre/Research Institute of the McGill University Health Centre
Cancer Research Society
Layout table for additonal information
Responsible Party: George Zogopoulos, Principal Investigator, McGill University Health Centre/Research Institute of the McGill University Health Centre
ClinicalTrials.gov Identifier: NCT04318834    
Other Study ID Numbers: 2020-6112
First Posted: March 24, 2020    Key Record Dates
Last Update Posted: March 24, 2020
Last Verified: March 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by George Zogopoulos, McGill University Health Centre/Research Institute of the McGill University Health Centre:
Biliary tract cancer
Cholangiocarcinoma
Molecular Profiling
Whole Genome Sequencing
Whole Transcriptome Sequencing
Additional relevant MeSH terms:
Layout table for MeSH terms
Biliary Tract Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Neoplasms
Biliary Tract Diseases
Digestive System Diseases